Jasper Therapeutics, Inc.
JSPR
$0.46
$0.00-0.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -18.48% | -21.60% | 25.19% | 18.24% | 41.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.31% | -12.72% | 69.30% | 44.65% | 42.65% |
| Operating Income | 39.31% | 12.72% | -69.30% | -44.65% | -42.65% |
| Income Before Tax | 62.58% | -0.53% | -83.25% | -54.73% | -46.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 62.58% | -0.53% | -83.25% | -54.73% | -46.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 62.58% | -0.53% | -83.25% | -54.73% | -46.68% |
| EBIT | 39.31% | 12.72% | -69.30% | -44.65% | -42.65% |
| EBITDA | 39.87% | 11.46% | -70.88% | -45.58% | -43.56% |
| EPS Basic | 80.41% | 9.35% | -79.09% | -37.35% | -7.94% |
| Normalized Basic EPS | 81.47% | 18.09% | -79.09% | -37.35% | -7.76% |
| EPS Diluted | 80.41% | 9.35% | -79.09% | -37.35% | -7.94% |
| Normalized Diluted EPS | 81.47% | 18.09% | -79.09% | -37.35% | -7.76% |
| Average Basic Shares Outstanding | 90.98% | 10.90% | 2.32% | 12.65% | 35.89% |
| Average Diluted Shares Outstanding | 90.98% | 10.90% | 2.32% | 12.65% | 35.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |